Opinion|Videos|March 24, 2025
Linda’s Treatment History and Challenges in Coping With Multiple Relapses
Author(s)Saad Usmani, MD, Amrita Krishnan, MD
Panelists discuss how multiple myeloma patients often navigate through numerous treatment regimens over their disease course, frequently cycling through five to 10 different therapeutic approaches since diagnosis, with the greatest challenges being management of cumulative side effects, emotional fatigue from repeated relapses and maintaining hope while facing increasingly limited options as they progress to late-line therapy.
Advertisement
Video content above is prompted by the following:
- How many different treatment regimens have you received since your diagnosis, and what have been your biggest challenges in coping with multiple relapses?
Advertisement
Related to this article
The FDA flagged potential safety signals for colitis with Ibrance, Kisqali and Verzenio, and heart inflammation with melanoma drugs. No causal link is confirmed.
A biomarker test changed one mother’s diagnosis from suspected glioblastoma to ependymoma, but the report written in October did not reach her until December.
Anktiva is now approved for BCG-unresponsive papillary-only bladder cancer. Here’s what the bladder-sparing option involves, from timeline to risks.
The approval adds patients with high-grade papillary-only tumors, based on trial data showing a 62% complete response rate in patients with carcinoma in situ.
The 2026 cancer report found U.S. cancer death rates continued to fall from 2019 to 2023, largely due to lung cancer progress, while diagnoses rose slightly among women.
Patients with a newly identified tumor state had shorter survival following chemotherapy and immunotherapy, potentially helping doctors identify those at greater risk of poor outcomes.
Longer follow-up of the phase 2 LUNAR trial showed a 62% lower risk of progression, additional hormone therapy or death with 177Lu-PNT2002 plus radiation.
Medicare's cap on out-of-pocket drug costs has made cancer pills more affordable, but premiums, formularies and prior authorization rules still vary widely. Here's a checklist.
Advertisement
Advertisement
Trending on CURE
1
FDA Expands Anktiva Approval in BCG-Unresponsive Bladder Cancer
2
Radioligand Plus Radiation Delays Prostate Cancer Progression to 17.6 Months
3
What Is a Personalized Cancer Vaccine? What Patients Should Know
4
Anktiva for Papillary Bladder Cancer: What Patients Should Know
5